Navigation Links
Phidea Srl and Marvin Research Srl Announce Completion of Merger
Date:1/22/2009

MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a CRO focused on Phase I to Phase IV clinical trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080122/335477 )

The new company will be named Phidea Marvin S.r.l. and have legal and operating offices in Milan, Italy. The combined company will also continue to operate its offices in Madrid, Spain providing drug development services to companies in need of a single source for clinical research including design and management of pan-European clinical trials (Phase I - III), and post marketing studies (Phase IV). Services offered by the new company will include all aspects of the clinical trial process including: protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing. Observational and epidemiological studies will also continue to be performed.

Phidea Marvin specializes in cardiovascular, CNS, gastroenterology oncology, rheumatology and anti-infective studies and services a broad range of multinational pharmaceutical firms.

Vincenzo Cocuzza, M.D., Phidea-Marvin's Chief Executive Officer stated, "We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and especially the United States and will continue to look for strategic opportunities that allow us to realize our goals. The merger with Marvin moves us closer to our objectives by:

    - Adding a partner with a strong market position and reputation in
      specific therapeutic areas

    - Adding additional multinational customers

    - Reducing costs

    - Increasing the overall size of the organization to allow even larger
      studies to be performed.

We also believe that the Marvin and Phidea teams have built an impressive portfolio of accomplishments and will work together to become a leader in the CRO sector."

About Phidea S.r.l.

Phidea S.r.l. specializes in international clinical research. The firm was founded in 1982 in Milan, Italy. In 1991 it expanded its operations and organized its Spanish subsidiary, Phidea Spain, in Madrid, Spain. The firm and partners provide a complete range of services to pharmaceutical companies including product formulation, stability, clinical trial material manufacturing, and all phases of clinical research.

Staffed with renown scientist and medical doctors, Phidea services major pharmaceutical companies seeking premium research in the European Union.

About Marvin Research S.r.l.

Marvin Research was founded in January 1999 by Vincenzo Maresca, M.D., with a team of experts from several CROs. Based in Milan, Italy, the firm focuses on Phase I through Phase IV human clinical trials for multinational pharmaceutical companies. Marvin Research's services span the entire clinical program including preparation of protocols by medical experts, all aspects of monitoring and performance of the trial, and finally statistics and report generation.

    Phidea Marvin Management Team.

    Vincenzo Cocuzza, Chairman and CEO
    Vincenzo Maresca, Managing Director
    Aldo Cocuzza, Managing Director

    For more information regarding Phidea Marvin S.r.l. contact:

    Mr. Aldo Cocuzza, Director,
    +39-3939189389 or email at aldo.cocuzza@phideamarvin.com

    Phidea-Marvin S.r.l.
    International Clinical Research
    Via Cristoforo Colombo, 1.
    Corsico (Milan, Italy)




'/>"/>
SOURCE Phidea Marvin Srl
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
2. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
3. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
4. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
5. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
6. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
7. 2008 Human Research Protection Award Recipients Announced
8. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
9. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
10. Myeloperoxidase Research Expands
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com today evaluates ... SGYP ), Novo Nordisk A/S (NYSE: NVO ... Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ). These ... January 19 th , 2017, finishing near its session lows. ... dropped over 0.7%, while shares of health care companies in ...
(Date:1/20/2017)... , VAE, January 20, 2017 ... gestiegenen Bedarf an Nothilfe   Die internationale humanitäre ... für Hilfsgüter zu schaffen   Seine ... Premierminister der VAE sowie Herrscher von Dubai ... internationalen Stadt der Hilfe (International Humanitarian City IHC) zu ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
Breaking Medicine Technology:
(Date:1/23/2017)... Portland, Oregon (PRWEB) , ... January 23, 2017 ... ... systems, announced today it has earned organic certification under the USDA National Organic ... the USDA Organic Certification process, we have established organic production and handling systems ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events ... is the creation of published author, Charlotte Hotte, a North Carolina native, a mother ... of the book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, ...
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
Breaking Medicine News(10 mins):